Yi Feng, MD

Dr. Yi Feng serves as Head of Oncology Clinical Science, at Overland Pharmaceuticals.

Prior to Overland, Dr. Feng served as Senior Director of Oncology at Roche and led multiple successful registrational trials of Perjeta/Kadcyla/Herceptin SC/Tecentriq/Avastin for breast and gynecological cancers. Before joining Roche, Dr. Feng served as Associate Director at Merck Sharp & Dohme (MSD) working on Keytruda for gastric cancer, Therapeutic Area Lead for solid tumors at Janssen R&D working on Zytiga and Apalutamide for prostate cancer, and Medical Affair Manager at Novartis Oncology working on Ceritinib for non-small cell lung cancer. Previously, she also worked as Project Manager of Clinical Operations in oncology, diabetes mellitus, CVD, and nephrology for six years at Novartis, Sanofi-Aventis, and Novo Nordisk. Additionally, she worked at the Peking Union Medical College affiliated Hematology Hospital and Institute for seven years as a hematology physician and researcher before joining industry. Bringing over 15 years of industry experience, Dr. Feng has been actively involved in global and local registrational trials as well as successful NDA submissions in the US, EMA, and China.

Dr. Feng received her MS in Internal Medicine from Peking Union Medical College and her MD from Nanjing Medical University.